Liver Research, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Current Nutrition Reports, Год журнала: 2025, Номер 14(1)
Опубликована: Янв. 22, 2025
Язык: Английский
Процитировано
2
European Journal of Preventive Cardiology, Год журнала: 2025, Номер unknown
Опубликована: Фев. 27, 2025
Metabolic dysfunction-associated steatotic liver disease (MASLD) can be interpreted as the hepatic expression of metabolic syndrome, which is estimated to affect 30% adult population. Obesity, dyslipidaemia, arterial hypertension, and T2DM are considered significant risk factors MASLD. The relationship two-way with MASLD found in up 75% patients T2DM. Importantly, associated increased cardiovascular diseases (CVD) such arrhythmia, atherosclerotic heart disease, failure, CVD-associated mortality. In addition, present a high prevalence major adverse cardiac events, calls for systematic surveillance CVD This review focuses on pathophysiology behind development MASLD, types complications, morbidity survival, suggestions evaluation
Язык: Английский
Процитировано
2
World Journal of Hepatology, Год журнала: 2025, Номер 17(1)
Опубликована: Янв. 6, 2025
Due to sedentary lifestyle and rising prevalence of obesity, patients with general population those who are infected chronic hepatitis B found have metabolic dysfunction associated steatotic liver disease (MASLD). Both virus (HBV) infection MASLD can damage hepatocytes in their own way, but concomitant HBV-MASLD has its clinical implications. Cherry on top is the presence diabetes mellitus, hypertension or obesity which added more chances unfavorable outcomes these patients. In this article, we comment article by Wang et al published recent issue. This provides a comprehensive overview complex interaction between HBV-MASLD, HBV alone We discuss key findings from studies, including promising observed concurrent MASLD, warrants further research. The insights presented here offer renewed understanding interaction.
Язык: Английский
Процитировано
1
Nutrition Journal, Год журнала: 2025, Номер 24(1)
Опубликована: Янв. 14, 2025
The objective of this study was to investigate the association between sarcopenia and liver fibrosis in patients aged 18–59 years with metabolic dysfunction-associated steatotic disease (MASLD) assess potential as a risk factor for progression fibrosis. included 821 MASLD US cohort 3,405 Chinese cohort. Liver controlled attenuation parameters (CAP) stiffness measurements (LSM) were assessed by vibration-controlled transient elastography (VCTE) evaluate extent hepatic steatosis Sarcopenia measuring appendicular skeletal muscle mass (ASM) calculating ASMI. To analyze relationship sarcopenia, ASMI, fibrosis, logistic regression models, multivariate-adjusted restricted cubic spline (RCS) models employed, stratification interaction analyses. results demonstrated that exhibited markedly elevated significant advanced cirrhosis compared those without both cohorts. After adjusting confounding variables, identified an independent MASLD. A negative correlation observed ASMI severity progressive reduction associated increasing Additionally, non-linear feature evident some indicators. Subgroup analysis further corroborated finding harmful effect on consistent across all subgroups. may be Monitoring assist identifying individuals at patients.
Язык: Английский
Процитировано
1
Liver Research, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
1